Changes in appetite-regulating hormones following food intake are associated with changes in reported appetite and a measure of hedonic eating in girls and young women with anorexia nervosa

Mancuso, Christopher; Izquierdo, Alyssa; Slattery, Meghan; Becker, Kendra R.; Plessow, Franziska; Thomas, Jennifer J.; Eddy, Kamryn T.; Lawson, Elizabeth A.; Misra, Madhusmita

doi:10.1016/j.psyneuen.2019.104556

Cited by 24 publications

(24 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, it would be better to compare more patients with healthy controls of similar age, which can help to interpret olanzapine-induced appetite increase and metabolic changes are specifically related to its pharmacological properties. Further studies should focus on the mechanisms of increased appetite after olanzapine treatment (Koopmann et al, 2012;Sweeney et al, 2017;Mancuso et al, 2019). The reward system in striatal regions may be associated with antipsychoticassociated weight gain (Nielsen et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients

et al. 2020

View full text Add to dashboard Cite

Weight gain and metabolic disturbances, potentially influenced by increased appetite, are common effects of olanzapine treatment in patients with schizophrenia. In this study, we explored the association between olanzapine-induced weight gain and metabolic effects with increased appetite. Drug-naïve, first-episode schizophrenia patients were treated with olanzapine for 12 weeks. Assessments included time to increased appetite, body weight, body mass index, biochemical indicators of blood glucose and lipids, proportion of patients who gained more than 7% or 10% of their baseline weight upon treatment conclusion, patients who developed dyslipidemia, and Positive and Negative Syndrome Scale scores. In total, 33 patients with schizophrenia receiving olanzapine were enrolled and 31 completed the study. During the 12-week olanzapine treatment, 77.4% (24/31) patients had increased appetite with 58.1% (18/31) patients having increased appetite within the first 4 weeks. The mean time for increased appetite was 20.3 days. More patients in the increased appetite group increased their initial body weight by more than 7% after 12 weeks when compared to patients with unchanged appetite (22/24 [91.7%] vs. 3/7 [42.9%], p = 0.004). Earlier increased appetite led to more weight gain during the following month. Overall, 50% of patients in the increased appetite group had dyslipidemia after 12 weeks. Our results demonstrated that olanzapine induced significantly appetite increase in first-episode patients with schizophrenia and appetite increase played a key role in olanzapine-induced weight gain and dyslipidemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The results obtained in the patients with AN confirm previous reports, i.e., the serum fasting PYY concentrations were not significantly different from those of the healthy volunteers [ 77 , 80 , 81 , 82 ]. However, some other studies have reported an increase [ 83 ]. We expected PYY to be lower in malnourished patients; however, it remained unchanged as compared with the control group.…”

Section: Discussionmentioning

confidence: 99%

Neuropeptide Y and Peptide YY in Association with Depressive Symptoms and Eating Behaviours in Adolescents across the Weight Spectrum: From Anorexia Nervosa to Obesity

et al. 2021

View full text Add to dashboard Cite

Neuropeptide Y (NPY) and peptide YY (PYY) are involved in metabolic regulation. The purpose of the study was to assess the serum levels of NPY and PYY in adolescents with anorexia nervosa (AN) or obesity (OB), as well as in a healthy control group (CG). The effects of potential confounders on their concentrations were also analysed. Eighty-nine adolescents were included in this study (AN = 30, OB = 30, and CG = 29). Anthropometric measurements and psychometric assessment of depressive symptoms, eating behaviours, body attitudes, and fasting serum levels of NPY and PYY were analysed. The AN group presented severe depressive symptoms, while the OB group held different attitudes towards the body. The levels of NPY were lower in the AN and OB groups as compared with the CG. The PYY levels were higher in the OB group than in the AN group and the CG. The severity of eating disorder symptoms predicted fasting serum concentrations of NPY. Lower levels of NPY in AN, as well as in OB suggests the need to look for a common link in the mechanism of this effect. Higher level of PYY in OB may be important in explaining complex etiopathogenesis of the disease. The psychopathological symptoms may have an influence on the neurohormones regulating metabolism.

show abstract

“…In line with the aforementioned relationships between BDNF and functions relevant to AN, a growing number of studies have reported BDNF alterations in AN patients [ 18 , 32 , 33 , 34 , 35 ]. The first evidence for a role of BDNF in AN came from Nakazato et al [ 18 ], who reported significantly lower serum BDNF levels in a small sample of individuals (aged 14–34 years) with acute AN (acAN) compared to both healthy comparison participants (HC) and individuals with bulimia nervosa (BN).…”

Section: Introductionmentioning

confidence: 99%

“…The first evidence for a role of BDNF in AN came from Nakazato et al [ 18 ], who reported significantly lower serum BDNF levels in a small sample of individuals (aged 14–34 years) with acute AN (acAN) compared to both healthy comparison participants (HC) and individuals with bulimia nervosa (BN). Additionally, studies have shown relationships between BDNF and eating behavior in AN-R [ 33 ] as well as significantly lower BDNF levels in AN-R than in AN-BP [ 6 ]. The main finding of decreased BDNF levels in acAN has now been repeatedly evaluated and mostly confirmed [ 17 , 32 , 34 , 35 , 36 , 37 ], suggesting that lower BDNF levels may represent an adaptive phenomenon of the body to increase food intake and achieve metabolic homeostasis in the undernourished individual [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Is Serum BDNF Altered in Acute, Short- and Long-Term Recovered Restrictive Type Anorexia Nervosa?

et al. 2021

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF), a neurotrophin involved in the regulation of food intake and body weight, has been implicated in the development and maintenance of Anorexia nervosa (AN). The majority of previous studies reported lower BDNF levels in acutely underweight AN patients (acAN) and increasing levels after weight rehabilitation. Here, we investigated serum BDNF concentrations in the largest known AN sample to date, both before and after weight restoration therapy. Serum BDNF was measured in 259 female volunteers: 77 in-patient acAN participants of the restrictive type (47 reassessed after short-term weight rehabilitation), 62 individuals long-term recovered from AN, and 120 healthy controls. We validated our findings in a post-hoc mega-analysis in which we reanalyzed combined data from the current sample and those from our previous study on BDNF in AN (combined sample: 389 participants). All analyses carefully accounted for known determinants of BDNF (age, sex, storage time of blood samples). We further assessed relationships with relevant clinical variables (body-mass-index, physical activity, symptoms). Contrary to our hypotheses, we found zero significant differences in either cross-sectional or longitudinal comparisons and no significant relationships with clinical variables. Together, our study suggests that BDNF may not be a reliable state- or trait-marker in AN after all.

show abstract

Changes in appetite-regulating hormones following food intake are associated with changes in reported appetite and a measure of hedonic eating in girls and young women with anorexia nervosa

Cited by 24 publications

References 46 publications

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients

Neuropeptide Y and Peptide YY in Association with Depressive Symptoms and Eating Behaviours in Adolescents across the Weight Spectrum: From Anorexia Nervosa to Obesity

Is Serum BDNF Altered in Acute, Short- and Long-Term Recovered Restrictive Type Anorexia Nervosa?

Contact Info

Product

Resources

About